ESTRO 2022 - Abstract Book

S259

Abstract book

ESTRO 2022

Table 2. Patient characteristics for institutional and literature review cohorts with UVA for OS, by subtype.

Conclusion PHLs are a rare subtype of NHL without clear treatment consensus. Primary hepatic DLBCL appears to be treated primarily with chemotherapy with adequate disease control. For indolent PHL, low-dose RT appears to achieve good disease control with minimal toxicity. Our RT data is limited by short follow-up duration of RT pts compared to pts who received chemotherapy, surgery or observation. However, our results are encouraging for the use of RT for appropriate patients with indolent PHL.

Mini-Oral: 07: Brachytherapy

MO-0297 Atlas based auto-segmentation in the delineation of rectum and bladder in intrauterine brachytherapy

P. Caricato 1,2 , S. Meregalli 3 , S. Trivellato 1 , E. Bonetto 3 , V. Faccenda 1,2 , D. Panizza 1,4 , S. Arcangeli 3,4 , E. De Ponti 1,4